ES2059670T3 - Una nueva familia de anticuerpos modificados, de alta afinidad, para el tratamiento del cancer. - Google Patents
Una nueva familia de anticuerpos modificados, de alta afinidad, para el tratamiento del cancer.Info
- Publication number
- ES2059670T3 ES2059670T3 ES89119361T ES89119361T ES2059670T3 ES 2059670 T3 ES2059670 T3 ES 2059670T3 ES 89119361 T ES89119361 T ES 89119361T ES 89119361 T ES89119361 T ES 89119361T ES 2059670 T3 ES2059670 T3 ES 2059670T3
- Authority
- ES
- Spain
- Prior art keywords
- human
- sequences
- antibodies
- cancer treatment
- modified antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Optics & Photonics (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
ESTE INVENTO CONCIERNE A UNA FAMILIA DE ANTICUERPOS QUIMERICOS CON ALTAS AFINIDADES A UN PESO MOLECULAR ALTO, ANTIGENOS GLICOPROTEINAS SIALILATADOS ASOCIADOS CON TUMOR (TAG72) DE ORIGEN HUMANO. ESTOS ANTICUERPOS TIENEN (1) SECUENCIAS VH Y VL ANIMALES DE ALTA AFINIDAD QUE MEDIAN EL TAG-72 QUE ATA Y (2) REGIONES CH Y CL HUMANAS. ELLOS ESTAN PENSADOS PARA PRODUCIR SIGNIFICANTEMENTE EFECTOS LATERALES MAS PEQUEÑOS CUANDO SE ADMINISTRA A PACIENTES HUMANOS POR VIRTUD DE SUS CAMPOS DE ANTICUERPOS CDH Y CL HUMANOS. SON DESCUBIERTAS LAS SECUENCIAS DE ACIDOS AMINO Y NUCLEOTIDO DE SECUENCIAS IDIOTIPO VHATAGVH, CC46VH, CC49H, CC83VH, Y CC92VH, Y CC49L, CC83VL, Y CC92VL, COMO TAMBIEN METODOS EN VIVO DE TRATAMIENTO Y DIAGNOSTICO QUE USAN ESOS ANTICUERPOS QUIMERICOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25994388A | 1988-10-19 | 1988-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2059670T3 true ES2059670T3 (es) | 1994-11-16 |
Family
ID=22987104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES89119361T Expired - Lifetime ES2059670T3 (es) | 1988-10-19 | 1989-10-18 | Una nueva familia de anticuerpos modificados, de alta afinidad, para el tratamiento del cancer. |
Country Status (21)
Country | Link |
---|---|
EP (2) | EP0397821A4 (es) |
JP (1) | JP2935520B2 (es) |
KR (1) | KR0161525B1 (es) |
AR (1) | AR242434A1 (es) |
AT (1) | ATE111519T1 (es) |
AU (2) | AU4429989A (es) |
BR (1) | BR8907126A (es) |
CA (1) | CA2000913C (es) |
DE (1) | DE68918217T2 (es) |
DK (1) | DK173089B1 (es) |
ES (1) | ES2059670T3 (es) |
FI (1) | FI103181B (es) |
HK (1) | HK162795A (es) |
HU (1) | HU218093B (es) |
IE (1) | IE64966B1 (es) |
IL (1) | IL92037A (es) |
NO (1) | NO301075B1 (es) |
NZ (1) | NZ231012A (es) |
PT (1) | PT92013B (es) |
WO (1) | WO1990004410A1 (es) |
ZA (1) | ZA897858B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US6121424A (en) * | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5976531A (en) * | 1990-04-19 | 1999-11-02 | The Dow Chemical Company | Composite antibodies of human subgroup IV light chain capable of binding to tag-72 |
US6495137B1 (en) * | 1990-04-19 | 2002-12-17 | The Dow Chemical Company | Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
ES2199216T3 (es) * | 1991-07-15 | 2004-02-16 | The Wellcome Foundation Limited | Produccion de anticuerpos. |
WO1993012231A1 (en) * | 1991-12-13 | 1993-06-24 | Dow Chemical (Australia) Limited | Composite antibodies of human subgroup iv light chain capable of binding to tag-72 |
AU696627B2 (en) * | 1991-12-13 | 1998-09-17 | Dow Chemical Company, The | Composite antibodies of human subgroup IV light chain capable of binding to TAG-72 |
WO1994012520A1 (en) * | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
CA2117477C (en) | 1992-12-11 | 2001-06-12 | Peter S. Mezes | Multivalent single chain antibodies |
US6348581B1 (en) | 1996-10-31 | 2002-02-19 | The Dow Chemical Company | High affinity humanized anti-TAG-72 monoclonalantibodies |
DE69829001T2 (de) * | 1998-02-25 | 2006-03-23 | The Dow Chemical Co., Midland | Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72 |
US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
CA2490659C (en) | 2002-06-28 | 2014-08-19 | Syed V. S. Kashmiri | Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors |
DE10311248A1 (de) * | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
WO2005021594A2 (en) | 2003-08-29 | 2005-03-10 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US73685A (en) * | 1868-01-21 | Improvement in ploughs | ||
GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
FR2788040B1 (fr) * | 1998-12-31 | 2001-03-23 | Airsec Sa | Distributeur d'objets |
-
1989
- 1989-10-04 WO PCT/US1989/004402 patent/WO1990004410A1/en active IP Right Grant
- 1989-10-04 IE IE334789A patent/IE64966B1/en not_active IP Right Cessation
- 1989-10-04 BR BR898907126A patent/BR8907126A/pt not_active Application Discontinuation
- 1989-10-04 EP EP19890911974 patent/EP0397821A4/en not_active Withdrawn
- 1989-10-04 KR KR1019900701297A patent/KR0161525B1/ko not_active IP Right Cessation
- 1989-10-04 HU HU255/89A patent/HU218093B/hu not_active IP Right Cessation
- 1989-10-04 AU AU44299/89A patent/AU4429989A/en not_active Abandoned
- 1989-10-04 JP JP1511127A patent/JP2935520B2/ja not_active Expired - Fee Related
- 1989-10-13 NZ NZ231012A patent/NZ231012A/en unknown
- 1989-10-17 ZA ZA897858A patent/ZA897858B/xx unknown
- 1989-10-17 PT PT92013A patent/PT92013B/pt not_active IP Right Cessation
- 1989-10-18 ES ES89119361T patent/ES2059670T3/es not_active Expired - Lifetime
- 1989-10-18 AT AT89119361T patent/ATE111519T1/de not_active IP Right Cessation
- 1989-10-18 DE DE68918217T patent/DE68918217T2/de not_active Expired - Fee Related
- 1989-10-18 CA CA002000913A patent/CA2000913C/en not_active Expired - Fee Related
- 1989-10-18 IL IL92037A patent/IL92037A/en not_active IP Right Cessation
- 1989-10-18 EP EP89119361A patent/EP0365997B1/en not_active Expired - Lifetime
- 1989-10-19 AU AU43540/89A patent/AU633026B2/en not_active Ceased
- 1989-10-19 AR AR89315213A patent/AR242434A1/es active
-
1990
- 1990-06-18 FI FI903056A patent/FI103181B/fi active IP Right Grant
- 1990-06-18 NO NO902696A patent/NO301075B1/no not_active IP Right Cessation
- 1990-06-19 DK DK199001499A patent/DK173089B1/da not_active IP Right Cessation
-
1995
- 1995-10-19 HK HK162795A patent/HK162795A/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2059670T3 (es) | Una nueva familia de anticuerpos modificados, de alta afinidad, para el tratamiento del cancer. | |
US5998580A (en) | Photosensitive caged macromolecules | |
JP7288402B2 (ja) | 細胞医療用の標的リガンド-ペイロードによる薬剤デリバリー | |
ES2292211T3 (es) | Compuestos y metodos para modular la permeabilidad de los tejidos relacionada con ocludina. | |
ATE446365T1 (de) | Menschliches fgf-21 gen und genexpressionsprodukte | |
AR003423A1 (es) | Anticuerpos monoclonales humanos de alta afinidad especificos de la proteina- f del rsv, celulas eucarioticas transfectadas; secuencia de adn y vector de expresion que lo codifican; metodo que utiliza los anticuerpos; una composicion farmaceutica que los contiene; metodo para detectar rsv y un kit de ensayo. | |
PA8535501A1 (es) | Anticuerpos contra el receptor del factor de crecimiento similar a insulina | |
ATE214943T1 (de) | Therapeutische zusammensetzungen die monoklonale antikörper enthalten gegen den menschlichen rezeptor für epidermalen wachstumsfaktor | |
DE60234793D1 (de) | LIVP Stamm von Vaccinia-Virus zur Diagnose und Behandlung von Tumoren | |
KR927003816A (ko) | Cd3에 대한 항체 | |
AR010752A1 (es) | COMPUESTOS QUE SE ENLAZAN A Y ACTIVAN UN RECEPTOR DE LA TROMBOPOYETINA; COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, SU USO PARA LA PREPARACION DE MEDICAMENTOS, Y PROCESO PARA PREPARAR DICHA COMPOSICIoN. | |
ATE536375T1 (de) | Menschliche igm antikörper, welche die fähigkeit besitzen, den wiederaufbau der myelinstruktur zu induzieren und deren diagnostische und therapeutische anwendung im zentralen nervensystem | |
CN106414500A (zh) | 抗-wt1/hla双特异性抗体 | |
ES2542861T3 (es) | Composiciones farmacéuticas capaces de inducir la apoptosis en células tumorales, útiles para el diagnóstico y tratamiento de leucemia linfocítica crónica-B | |
EP3065722A2 (en) | Nucleic acid nanostructures for in vivo agent delivery | |
ATE287958T1 (de) | Verbesserte krebstherapie | |
CN104592352A (zh) | 与缺血性脑卒中组织特异性结合的hgg多肽及其应用 | |
ES2239126T3 (es) | Uso de anticuerpos monoclonales antiferritinas en el tratamiento de determinados canceres. | |
KR102018774B1 (ko) | Glypican-3에 선택적으로 결합하는 압타머 및 이의 용도 | |
JP2010502201A (ja) | ガリウム−68で標識されたアプタマー | |
Wade | Hybridomas: A potent new biotechnology | |
PT866861E (pt) | Clonagem molecular e caracterizacao de moleculas relacionadas com relaxina e com a familia dos ligandos da insulina | |
JPH01221327A (ja) | 形質転換又は腫瘍細胞を選択的に死滅させるための剤として使用されるセット又はキット | |
JP2005513108A (ja) | ポリペプチド、及びドキソルビシンとドキソルビシンに基づく薬剤とを含有するポリペプチドの接合体 | |
ATE407944T1 (de) | Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 365997 Country of ref document: ES |